IP Library Granted Patent US 10,435,714
Granted Patent B2
US 10,435,714 · App. 15/896,433 · Granted Oct 8, 2019

Nucleic acid-guided nucleases

Inventors: Ryan T. Gill (Denver, CO); Andrew Garst (Boulder, CO); Tanya Elizabeth Warnecke Lipscomb (Boulder, CO)
Assignee: INSCRIPTA, INC.
C12N15/902C12N9/22C12N15/11C12N15/111C12N15/70C12N15/81C12N15/85C12N15/905C12N15/907C12N2310/20C12N2800/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,435,714
App. No.
15/896,433
Granted
Oct 8, 2019
Kind
B2
Abstract

Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.

Claims (31)

1. A nucleic acid-guided nuclease system comprising:

(a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO: 2;

(b) a heterologous engineered guide nucleic acid for complexing with the nucleic acid-guided nuclease, wherein said heterologous engineered guide comprises SEQ ID NO: 88, and

(c) an editing sequence having a change in sequence relative to the sequence of a target region; wherein the system results in an edit in the target region facilitated by the nuclease, the heterologous engineered guide nucleic acid, and the editing sequence.

2. The system of claim 1 , wherein the target region is within a eukaryotic cell.

3. The system of claim 1 , wherein the target region is within a bacterial cell.

4. The system of claim 1 , wherein the target region is within a plant cell.

5. The system of claim 1 , wherein the target region is within a mammalian cell.

6. The system of claim 1 , wherein the heterologous engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid.

7. A method of modifying a target region, the method comprising:

(a) contacting a sample comprising the target region with:

(i) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO: 2; and

(ii) a heterologous engineered guide nucleic acid for complexing with the nucleic acid-guided nuclease, wherein said heterologous engineered guide comprises the sequence of SEQ ID NO: 88 and

(b) allowing the nuclease and heterologous guide nucleic acid to modify the target region.

8. The method of claim 7 , wherein the sample is further contacted with (iii) an editing sequence having a change in sequence relative to the sequence of the target region.

9. The method of claim 8 , wherein modifying the target results in an edit in the target region facilitated by the nuclease, the heterologous engineered guide nucleic acid, and the editing sequence.

10. The method of claim 8 , wherein the heterologous engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid.

11. The method of claim 8 , wherein the editing sequence further comprises a mutation in a protospacer adjacent motif (PAM) site.

12. The method of claim 7 , wherein the target region is within a eukaryotic cell.

13. The method of claim 7 , wherein the target region is within a bacterial cell.

14. The method of claim 7 , wherein the target region is within a plant cell.

15. The method of claim 7 , wherein the target region is within a mammalian cell.

16. A nucleic acid-guided nuclease system comprising:

(a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO: 2;

(b) a heterologous engineered guide nucleic acid for complexing with the nucleic acid-guided nuclease, wherein said heterologous engineered guide comprises SEQ ID NO: 93, and SEQ ID NO: 94, and

(c) an editing sequence having a change in sequence relative to the sequence of a target region; wherein the system results in an edit in the target region facilitated by the nuclease, the heterologous engineered guide nucleic acid, and the editing sequence.

17. The system of claim 16 , wherein the target region is within a eukaryotic cell.

18. The system of claim 16 , wherein the target region is within a bacterial cell.

19. The system of claim 16 , wherein the target region is within a plant cell.

20. The system of claim 16 , wherein the target region is within a mammalian cell.

21. The system of claim 16 , wherein the heterologous engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Sep 15, 2025
From: INSCRIPTA, INC.,; MANUS INSCRIPTA, INC.
To: MANUS INSCRIPTA, INC.
Reel/Frame 072252/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2018
From: GILL, RYAN T.; GARST, ANDREW; LIPSCOMB, TANYA ELIZABETH WARNECKE
To: MUSE BIOTECHNOLOGY, INC.
Reel/Frame 045571/0500 →
CHANGE OF NAME Recorded Mar 27, 2018
From: MUSE BIOTECHNOLOGY, INC.
To: INSCRIPTA, INC.
Reel/Frame 045571/0502 →
Continuity (2)
Continuation 15631989 · Jun 23, 2017
Related Publication 20180371497A1 · Dec 27, 2018
Cited By (1)
US 12,195,749